Newsletter Subject

It Was Run by Crooks — Now It's Bigger Than AI

From

energyandcapital.com

Email Address

newsletter@energyandcapital.com

Sent On

Fri, Aug 14, 2020 06:24 PM

Email Preheader Text

Biotechnology has greatly extended our lives already. But it's not done. And the next phase of devel

Biotechnology has greatly extended our lives already. But it's not done. And the next phase of development in the field of biogerontology could be the key to continued life extension. Biotechnology has greatly extended our lives already. But it's not done. And the next phase of development in the field of biogerontology could be the key to continued life extension. [Energy and Capital logo] It Was Run by Crooks — Now It's Bigger Than AI [Luke Burgess Photo] By [Luke Burgess]( Written Aug 14, 2020 What's your biggest fear? Snakes? Spiders? Sharks? Heights? Clowns? Airplane crashes? Public speaking? Heart Disease? Wolverines? Think of your biggest fear and hold it in your mind for a moment. (And email me if your greatest fear is in fact wolverines... because I have a lot of questions, beginning with why you are around wolverines in the first place.) Whatever you're thinking of right now can most likely be boiled down to the fear of one of two things: death or suffering. What I mean is people generally aren't afraid of snakes as much as they're afraid of the snake bite. The bite does all the damage to cause suffering and, maybe in rare cases, death. In the same way, people aren't necessarily afraid of public speaking as much as they're afraid of making mistakes when speaking publicly — thus suffering from embarrassment. "Small Pill Could Save Millions of Lives" — Kevin O’Leary [kevin oleary shark tank]( Chronic diseases like alcoholism, opioid addiction, diabetes, and depression can be a death sentence for millions of sufferers. Regular treatments work only 30% of the time and can take years. Now the FDA has given the go-ahead to a small pill that wipes out these diseases with just one or two doses. And elite research institutions, like Johns Hopkins, Stanford, and Harvard, have replicated and confirmed the results. "Mr. Wonderful," Kevin O’Leary, has already invested millions. [Details here...]( Likewise, if I had to guess, an individual wouldn't be as afraid of wolverines as he'd be afraid of what wolverines might (and probably will) do to him — like claw up his leg and bite his neck. That's... quite undesirable. Rare sighting of a wolverine in Washington state earlier this year[wolverine]Image credit: istockphoto.com/Alphotographic If you asked me my greatest fear, I'd tell you heights. I can't even watch a video of someone standing precariously high without my chest tightening and my palms sweating. But it's really not the elevation that makes me nervous — it's not even falling off. What's really got me worried is the sudden stop at the bottom. It's not the drop. It's the plop. All this is to say most (if not all) of our fears generally have layers. And at the core of most of our fears are death and suffering. But here's the rub... And you know where this is going... Suffering and death are inevitable parts of life. Every human being that has ever walked the Earth has experienced both. That's where we find a dilemma that's been haunting humanity forever: No one wants to suffer. No one wants to die. But everyone must experience both. As a result, there is (and always has been) a massive demand for methods to alleviate those fears. From philosophy to pharmaceuticals, humans have spent an unimaginable amount of time and resources softening fears of suffering and death. Let's just consider anti-aging cosmetics for a moment... You could argue there is some philosophy that doesn't exactly aim to alleviate fears of aging and death. And of course, pharmaceuticals have a wide variety of purposes. But there's no inferring what cosmetic companies are trying to sell consumers with anti-aging products: beauty and youth. It's right in the name "anti-aging." The desire for beauty and youth is most often pinned on societal pressure. But I'd argue part of that desire is also one of many ways people use to alleviate the fear of death. If you look younger in the mirror and maybe even feel younger as a result, it's easier to convince yourself you're that much further away from death. The global anti-aging cosmetics market is huge. In 2018 it was estimated to be worth over $50 billion. That's bigger than the AI market today. In fact, that's about the same size as the global solar energy market! And the anti-aging cosmetics market is only estimated to grow from here. Forecasts estimate the global market will grow by about 5% or 6% CAGR over the next decade. And cosmetics are really just one small part of the growing anti-aging market. Three Stocks to Play This $12 Trillion Investment Opportunity Right now, 5G is taking the world by storm. And within the next few years, it’s expected to create a $12 trillion tsunami of cash. Investors who position themselves properly stand to become millionaires. [Here are three stocks to get you started.]( For centuries, anti-aging practices were mostly relegated to the work of charlatans. More recently, the cosmetics industry took over. But new research into genetics and aging have allowed biogerontology (the real study of the biological basis of aging and age-related diseases) to flourish and gain legitimacy. Anti-aging is becoming less snake oil and more real science. But there's something you should know... This new research isn't working toward human immortality. I'm sorry, but you're never going to live forever. Nevertheless, new breakthroughs in anti-aging technology do promise to make you healthier and live longer. As my colleague Jeff Siegel says, anti-aging technology (despite the name) won't produce a Fountain of Youth. But it will produce a fountain of health. For the past several months, Jeff has been studying the anti-aging market and the real science behind age-extending, groundbreaking biotechnologies. And he's come up with some really unique opportunities and ideas that I don't think most people have really considered. To read more about Jeff's recent research, [click here](. Again, we're not talking about immortality. Instead, we're talking about significantly extending the human life span. And the truth is that's been happening over the course of thousands of years. Prior to the 20th century, the average global life expectancy for a human being was under 40 years old. In the past 100 years alone, new developments and better technology have increased life expectancy past 70. That's an 80% increase in about 100 years. So we're not talking about science fiction here. Biotechnology has greatly extended our lives already. But it's not done. And the next phase of development in the field of biogerontology could be the key to continued life extension. [Check out Jeff's research](. It's very easy to be skeptical about anti-aging technology. That's understandable. As I mentioned, for most of human history the market has been controlled by snake oil salesman and cosmetic marketing. But there is some real science behind the biological basis of aging and age-related disease that can be addressed with new research. [Take a look at one of Jeff's most recent reports on anti-aging technology here](. I guarantee there are no wolverine attacks involved. Until next time, [Luke Burgess Signature] Luke Burgess As an editor at Energy and Capital, Luke’s analysis and market research reach hundreds of thousands of investors every day. Luke is also a contributing editor of Angel Publishing’s Bull and Bust Report newsletter. There, he helps investors in leveraging the future supply-demand imbalance that he believes could be key to a cyclical upswing in the hard asset markets. For more on Luke, go to his [editor’s page](. Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [Miguel Lozano and the Future of the Entrepreneurial Spirit]( [Lithium Battery Investments]( [Will the Government Confiscate Your Gold?]( [Bet on Mr. Gold]( [How to Profit From the End of Aging]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Energy and Capital](, Copyright © 2020, [Angel Publishing LLC](. All rights reserved. 3 E Read Street, Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Energy and Capital]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. ---------------------------------------------------------------

EDM Keywords (206)

youth years worth worried world work wolverines wolverine within wipes well want view video us understandable trying truth time thousands thinking think tell talking taking sure suffering suffer subscription studying storm statement started spent sources sorry something solicitation snakes skeptical size sent sell security securities say sale run rub right reviewing result research republished replicated reliable recently received receive really read question purposes purchase publisher publication prospectus promise profit produce probably privacy position plop play philosophy people opinion one offer next nervous neck name much moment mirror mind millions methods mentioned mean maybe may market manage makes make made lot look link likewise likely like leveraging leg leary layers know key jeff investment intention information inferring individual indirectly important ideas human huge hold heights healthier health harvard happening guess guarantee grow given get genetics future fountain flourish find field fears fear fda fact expression experienced expected estimated ensure energy end email elevation editors editor easy easier earth drop done diseases dilemma die development desire depression decrease death damage crooks create course cosmetics core convince controlled content consulting consultants confirmed company come charlatans capital buy bull bottom boiled bite biotechnology bigger believe beauty away author asked anyone analysis always also alleviate aging afraid addressed accuracy 5g 30 2018

Marketing emails from energyandcapital.com

View More
Sent On

08/12/2024

Sent On

06/12/2024

Sent On

06/12/2024

Sent On

04/12/2024

Sent On

04/12/2024

Sent On

02/12/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.